Project Grant R21HL170177
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $143,461 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct high-resolution phenotyping of hemodynamic consequences in adults who have undergone thoracic endovascular aortic repair (TEVAR) for descending thoracic aortic aneurysm. The research assesses how graft material stiffness following TEVAR affects pressure, wave reflections, and pulsatility in...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $471,280 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate in silico and in vitro modeling platforms for comparing surgical repair strategies in atrioventricular septal defects (AVSD). The research will create matched computational and laboratory-based functional models of atrioventricular valves from AVSD patients to identify optimal surgical...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $704,851 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance tissue characterization methods for prognostication and therapeutic response prediction in functional tricuspid regurgitation. The project leverages newly developed CMR techniques optimized for the thin-walled right ventricle, including high-resolution 3D navigator late...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $697,198 to the University of Texas at Austin on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-biased integrin-mediated endothelialization processes for precision vascular graft design. The recipient is conducting research to identify how biological sex affects endothelial cell behavior in response...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Austin $238,858 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop personalized prediction models for HER2-induced cardiovascular adverse events in older women with breast cancer using artificial intelligence and machine learning. The award funds a cohort study using 2011–2022 Surveillance, Epidemiology, and End Results (SEER)–Medicare data linked with American...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $163,160 on February 12, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize neoaortic valve biomechanics in the Ross procedure for congenital aortic valve disease. The research addresses durability limitations of the Ross procedure, in which a patient's healthy pulmonic valve is translocated to the aortic position. While the procedure offers a living valve replacement...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...